VHL is an inclusion criterion in 4 clinical trials for renal cell carcinoma, of which 3 are open and 1 is closed. Of the trials that contain VHL status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 3 are phase 2 (3 open) [4].

VHL is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain VHL status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

VHL is an inclusion criterion in 3 clinical trials for von Hippel-Lindau syndrome, of which 2 are open and 1 is closed. Of the trials that contain VHL status and von Hippel-Lindau syndrome as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open) [4].

VHL is an inclusion criterion in 2 clinical trials for adrenal gland pheochromocytoma, of which 0 are open and 2 are closed. Of the trials that contain VHL status and adrenal gland pheochromocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (0 open) [4].

VHL is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains VHL status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for cerebellar hemangioblastoma, of which 0 are open and 1 is closed. Of the trial that contains VHL status and cerebellar hemangioblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

VHL is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VHL status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VHL is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains VHL status and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

VHL is an inclusion criterion in 1 clinical trial for paraganglioma, of which 0 are open and 1 is closed. Of the trial that contains VHL status and paraganglioma as inclusion criteria, 1 is phase 2 (0 open) [4].

VHL is an inclusion criterion in 1 clinical trial for retinal hemangioblastoma, of which 0 are open and 1 is closed. Of the trial that contains VHL status and retinal hemangioblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

VHL is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].